CASI Pharmaceuticals (CASIF) Long-Term Investments (2021 - 2025)

CASI Pharmaceuticals has reported Long-Term Investments for 5 years, with the latest figure at $1.7 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Investments fell 10.3% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (down 10.3% YoY), and the FY2025 full-year result was $1.7 million, down 10.3% from the prior year.
• Long-Term Investments for Q4 2025 stood at $1.7 million, roughly flat from $1.7 million in the prior quarter.
• The five-year high for Long-Term Investments was $3.6 billion in Q2 2023, with the low at $1.7 million in Q1 2024.
• Historically, Long-Term Investments has averaged $823.8 million across 5 years, with a median of $4.4 million in 2022.
• The largest YoY upside for Long-Term Investments was 113490.5% in 2025 against a maximum downside of 99.9% in 2025.
• CASI Pharmaceuticals' Long-Term Investments stood at $40.1 million in 2021, then slumped by 89.04% to $4.4 million in 2022, then jumped by 38235.61% to $1.7 billion in 2023, then slumped by 99.89% to $1.9 million in 2024, then fell by 10.3% to $1.7 million in 2025.
• The last three Long-Term Investments figures came in at $1.7 million (Q4 2025), $1.7 million (Q3 2025), and $1.7 million (Q2 2025), per Business Quant data.